Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization

Infection and Immunity

Volumn 67, Issue 8, 1999, Pages 4276-4279

  Barackman, J D ^a   Ott, G ^a   O'Hagan, D T ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; FEMALE; INFLUENZA; INFLUENZA VACCINATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032769773     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.8.4276-4279.1999     Document Type: Article

References (29)

1. Andrews, H. P., R. D. Snee, and M. H. Sarner. 1980. Graphical display of means. Am. Statistician 34:195-199.
2. Barchfeld, G. L., A. L. Hessler, M. Chen, M. Pizza, R. Rappuoli, and G. A. Van Nest. 1998. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine 17:695-704.
3. Bender, B. S., M. P. Johnson, and P. A. Small. 1991. Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immunology 72:514-519.
4. Bender, B. S., S. F. Taylor, D. S. Zander, and R. Cottey. 1995. Pulmonary immune response of young and aged mice after influenza challenge. J. Lab. Clin. Med. 126:169-177.
5. Clements, M. L., and I. Stephens. 1997. New and improved vaccines against influenza, p. 545-570. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (ed.), New generation vaccines. 2nd edition. Marcel Dekker, Inc., New York, N.Y.
6. De Haan, A., H. J. Geerligs, J. P. Huchshorn, G. J. M. Van Scharrenburg, A. M. Palache, and J. Wilschut. 1995. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13:155-162.
7. Dickingson, B. L., and J. D. Clements. 1996. Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant, p. 73-87. In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines. Academic Press, Inc., New York, N.Y.
8. 7a. Elson, C. O. 1996. Cholera toxin as a mucosal adjuvant, p. 59-72. In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines. Academic Press, Inc., New York, N.Y.
9. Ghendon, Y. 1989. The immune response of humans to live and inactivated influenza vaccines. Adv. Exp. Med. Biol. 257:37-45.
10. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of Escherichia coli heat-labile enterotoxin (LT) mutants with partial or total knock-out of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123-1132.
11. Glezen, P. W. 1982. Serious morbidity and mortality associated with influenza epidemics. Epidemiol. Rev. 4:25-44.
12. Harlow, E., and D. Lane. 1988. Immunoassay, p. 553-612. In Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
13. Hierholzer, J. C., and M. T. Suggs. 1969. Standardized viral hemagglutination and hemagglutination-inhibition tests. I. Standardization of erythrocyte suspensions. Appl. Microbiol. 18:816-823.
14. Hierholzer, J. C., M. T. Suggs, and E. C. Hall. 1969. Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation. Appl. Microbiol. 18:824-833.
15. Hoskins, T. W. 1979. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet i:33-35.
16. Johannsen, R., H. Moser, J. Hinz, H. J. Freisen, and H. Gruschkau. 1985. Quantitation of haemagglutinin of influenza Tween-ether split vaccines by immunodiffusion. Vaccine 3:235-240.
17. Oh, Y., K. Ohta, H. Kuno-Sakai, R. Kim, and M. Kimura. 1998. Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccine. Vaccine 10:506-511.
18. Patriarca, P. A., J. A. Weber, R. A. Parker, W. N. Hall, A. P. Kendal, M. S. Bregman, and L. B. Schonberger. 1985. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 253:1136-1139.
19. Pizza, M., M. Domenighini, W. Hol, V. Giannelli, M. R. Fontana, M. M. Giuliani, C. Magagnoli, S. Peppoloni, R. Manetti, and R. Rappuoli. 1994. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 14:51-60.
20. Powers, D. C., S. D. Sears, B. R. Murphy, B. Thumar, and M. L. Clements. 1989. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J. Clin. Microbiol. 27:2666-2671.
21. Powers, D. C. 1993. Influenza A virus-specific cytotoxic T-lymphocyte activity declines with advancing age. J. Am. Geriatr. Soc. 41:1-5.
22. Renegar, K. B., and P. A. Small, Jr. 1991. Immunoglohulin A mediation of murine nasal anti-influenza virus immunity. J. Virol. 65:2146-2148.
23. Riddiough, M. A., J. E. Sisk, and J. C. Bell. 1983. Influenza vaccination: cost-effectiveness and public policy. JAMA 249:3189-3195.
24. Tamura, S., H. Funato, Y. Hiroabayashi, Y. Suzuki, T. Nagamine, C. Aizawa, and T. Kurata. 1991. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur. J. Immunol. 21:1337-1344.
25. Tamura, S., Y. Ito, H. Asanuma, Y. Hirabayashi, Y. Suzuki, T. Nagamine, C. Aizawa, and T. Kurata. 1992. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol. 149:981-988.
26. Tamura, S., H. Asanuma, T. Tomita, K. Komase, K. Kawahara, H. Danbara, N. Hattori, K. Watanabe, Y. Suzuki, T. Nagamine, C. Aizawa, A. Oya, and T. Kurata. 1994. Escherichia coli heat-labile enterotoxin B subunit supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 12:1083-1089.
27. Treanor, J., G. Dumyati, D. O'Brien, M. A. Riley, G. Riley, S. Erb, and R. Betts. 1994. Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults. J. Infect. Dis. 169:402-407.
28. Ugozzoli, M., D. T. O'Hagan, and G. S. Ott. 1998. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 93:563-571.
29. Waldman, R. H., S. H. Wood, E. J. Torres, and P. A. Small, Jr. 1970. Influenza antibody response following aerosal administration of inactivated virus. Am. J. Epidemiol. 91:575-584.